Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 110 participants.
Also called NCT05610566
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 110 participants
- Sponsor
- Registry
-
NCT05610566
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT05610566. Allocation not applicable; no masking; primary purpose treatment. Start 2022-07-06 (actual); primary completion 2025-07-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China
- Condition
- Mitral Regurgitation
- Intervention (Device)
- the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System
- Lead sponsor
- Peijia Medical Technology (Suzhou) Co., Ltd.
- Collaborator
- West China Hospital
- Collaborator
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Collaborator
- The Second Affiliated Hospital of Harbin Medical University
Record details
- Record id
cardio:ct-nct05610566- Content hash
f5f0fc1a3631da473f17648a01e04974928cbbc76aa7e895d94c56c17d883769